Dual GIP/GLP-1 agonist research and comparisons.
4 articles
Peptides & Recovery
Semaglutide-based metabolic research protocols use diet-induced obesity (DIO) rodent models to study GLP-1R-mediated weight loss, glycemic improvement, and lipid remodeling. Guide to the semaglutide DIO research stack — compound selection, protocol design, dose escalation, and endpoints.
4 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Weight Loss & GLP-1
Head-to-head comparison of retatrutide (triple GIP/GLP-1/glucagon agonist) vs tirzepatide (dual GIP/GLP-1). Phase 2 and Phase 3 data, mechanism differences, and what the research says about each.
9 min read
Weight Loss & GLP-1
A mechanistic deep-dive into triple GIP/GLP-1/glucagon receptor co-agonism — why each receptor contributes distinct weight loss and metabolic effects, and why their combination is synergistic rather than merely additive.
8 min read
ZPHC
Tirze 15mg single vial by ZPHC. Dual GIP/GLP-1 agonist.
99%+· ZPHC
ZPHC
Tirze 25mg kit (5×5mg) by ZPHC. Dual GIP/GLP-1 agonist.
99%+· ZPHC
ZPHC
Tirze 30mg premixed AQ pen by ZPHC. Ready-to-inject dual agonist.
99%+· ZPHC
ZPHC
Tirze 75mg dual-chamber auto-mixing pen by ZPHC. Long-term supply.
99%+· ZPHC
For laboratory research only. Not for human consumption.
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer